Skip to main content
    R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $162.78
    -5.01 (-2.99%)

    Market Cap: $10.73B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Repligen Corporation (RGEN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Repligen (RGEN) trades at 79.8x trailing earnings and 11.4x sales. Its P/E of 79.8x is below its 5-year median of 83.5x. Its forward P/E is 60.2x. The median P/E across 11 similar companies is 20.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 32.6% higher over the next year. Its free cash flow yield is 1.2%.

    MultipleValue
    P/E (trailing)79.8x
    Forward P/E60.2x
    Price to sales11.4x
    Price to book4.4x
    EV/EBITDA91.0x
    Price to FCF86.3x
    EV/FCF84.7x
    PEG1.6
    FCF yield1.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 3.4% below 82.6x, its P/S is 13.6% below 13.2x and its P/B is 8.3% below 4.8x.

    MultipleCurrent5-year median10-year median
    P/E79.8x83.5x82.6x
    P/S11.4x12.8x13.2x
    P/B4.4x4.7x4.8x
    Medians of month-end values through Oct 2026: 48 to 60 months (5-year) and 108 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 51.6x in 2022 to 138.6x in 2024.

    Year endPriceP/EP/SP/B
    2025$163.8695.8x12.5x4.4x
    2024$143.94138.6xN/A4.1x
    2023$179.80103.9x15.8x5.1x
    2022$169.3151.6x11.8x5.1x
    2021$264.8486.5x22.0x8.7x
    2020$191.63115.4x27.8x6.9x
    2019$92.5088.1x16.6x4.6x
    2018$52.7471.3x11.9x4.0x
    2017$36.2851.8x9.9xN/A
    2016$30.8270.0x5.0xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RGEN

    What is RGEN's forward P/E ratio?

    Repligen has a forward P/E ratio of 60.2x.

    Is RGEN stock overvalued?

    GNG's valuation label for RGEN is Undervalued. Its P/E of 79.8x compares with a median of 20.7x across 11 similar companies.

    What is RGEN's price to sales ratio?

    Repligen has a price to sales ratio of 11.4x.

    What is Repligen's average P/E ratio over 5 years?

    Repligen's median P/E over the last 5 years is 83.5x, from 60 month-end values through Oct 2026.

    What is RGEN's PEG ratio?

    Repligen has a PEG ratio of 1.6.